Browse Studies — Arctuva

Phase 3

A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Study of Solriamfetol in Subjects With Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

CLARITY (Clinical Assessment of Response in the Treatment of Depression with Daytime Sleepiness Using Solriamfetol) is a Phase 3, double-blind, placebo-control…

Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms

Estimated

~$10 – $8,750

Axsome Therapeutics, Inc.NCT07484217

Observational

A Randomized, Double-Blind, Controlled Trial of Bright Light Therapy on All-Cause Excessive Daytime Sleepiness in Prader-Willi Syndrome

This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with …

Prader-Willi SyndromeExcessive Daytime SleepinessHyperphagia+3 more

Estimated

~$10 – $6,250

Maimonides Medical CenterNCT05939453

Phase 1

A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Excessive Daytime Sleepiness

Estimated

~$10 – $8,750

Centessa Pharmaceuticals (UK) LimitedNCT07082829